Q4 2024 Earnings Call Transcript March 13, 2025 REGENXBIO Inc. beats earnings expectations. Reported EPS is $-1.01, expectations were $-1.27. Operator: Welcome everyone to the Fourth Quarter and Year ...
Additionally, Unity Biotechnology also announced 3 Yehia Hashad, MD, executive vice president of research and development and ...
19 小时
TipRanks on MSNNurExone’s ExoPTEN Shows Promising Preclinical Results for Spinal Cord InjuryExoPTEN, which is advancing towards first-in-human trials. The study demonstrated that ExoPTEN significantly enhances motor function recovery and improves blood flow at spinal cord injury sites, ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果